Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer

Fig. 1

PD-L1 is a downstream target of METTL3. a The global content of m6A was examined by RNA methylation quantification assay. b The starplot presented the distribution of genes with both differential (hyper or hypo) methylation level (Y axis; |fold change| ≥ 1.5) and differential (up or down) gene expression level (X axis; |fold change| ≥ 1.5) in sh-METTL3 with control groups. c Volcano plot of changed m6A peaks was identified by MeRIP-seq in control and METTL3-knockdown MDA-MB-231cells. d Distribution of total m6A peaks in sh-control and sh-METTL3 groups were shown. e Top sequence motif was identified from MeRIP-seq. f Venn diagram showed the down-modified genes following METTL3 knockdown. g The mRNA expression levels of MDA-MB-231 and HCC38 cells were tested by qRT-PCR after 3-deazaadenosine (DAA) treatment in the indicated concentration. *p < 0.05; **p < 0.01

Back to article page